

The logo features the word "OncoVerity" in a dark blue, sans-serif font. The "o" in "Onco" is a light green color. Below the main text is the tagline "We Seek a World Where Cancer Never Wins" in a smaller, light green font. The background consists of two overlapping, light green circular shapes that are partially cut off by the edges of the frame.

OncoVerity

We Seek a World Where Cancer Never Wins

Forward looking statement


Information in this presentation and related comments of presenters contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are based on current expectations, forecasts, assumptions, and other information available to the company as of the date hereof. Forward-looking statements include, but are not limited to, implied and express statements about the company's strategy, future business plans, functionality, and capabilities; plans and timelines for clinical development of the company's therapies, including therapeutic potential and efficacy, clinical benefits, safety profiles, and plans to submit investigational new drug (IND) applications; the potential size of the commercial market for the company's treatment programs; the company's long-term financial targets, prospective financial results, return of capital plans, expectations about addressable markets and market share; and future business outlook, such as forward-looking statements about the company's expectations, beliefs, intentions, or strategies. All statements other than statements of historical facts contained in this presentation, including express or implied statements regarding our strategy, future financial conditions and operations, projected costs, plans, objectives of management and expected market growth, are forward-looking statements.

In some cases, forward-looking statements use terminology such as "anticipate", "believe", "could", "expect", "may", "estimate", "intend", "ongoing", "plan", "potential", "should", "will", and "would", although not all forward-looking statements contain these identifying words.

The Company's actual results, performance, or events may differ materially from these forward-looking statements made or implied due to a number of factors, risks, and uncertainties relating to the Company's business, including but not limited to: the timing and anticipated results of our current and future clinical trials, supply chain, strategy, and future operations; the risk that the results of prior preclinical and clinical studies may not be predictive of future results in connection with current or future clinical trials; the timing and outcome of any interactions with or approvals by regulatory authorities; obtaining, maintaining, and protecting our intellectual property; our relationships with existing and future investors and collaboration partners; the impacts of current macroeconomic and geopolitical events. The Company disclaims any warranties or representations (expressed or implied) related to the accuracy of forward-looking statements and you should not place undue reliance on our forward-looking statements. The company assumes no obligation and disclaims any obligation to update any forward-looking or other information included in this presentation, whether as a result of new information, future events or otherwise. This presentation contains trademarks, trade names, and trademarks of other companies, which are the property of their respective owners. This presentation is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to

local law or regulation or require any registration or licensing within such jurisdiction.

OncoVerity



Company highlights



OncoVerity is pioneering AI-enabled precision medicine, bringing transformative breakthrough therapies to patients



Cusatuzumab (Cusa) brings new hope to AML patients based on promising clinical evidence



The OV-AML-1231 trial enables an efficient and accelerated route to market



Ready to execute on pipeline expansion; Cusatuzumab and AML are only the beginning

Highly experienced management team with ~100 years of combined track record in oncology and biopharma



Max Colao, MBA

Chief Executive Officer & Board Chairman

- Over 30 years biotech leadership experience in oncology, inflammation and rare diseases
- Leadership across 13 therapeutic launches in the US and ex-US
- Track record in both startup and large biotech



Clay Smith, MD

Founder; Scientific Advisor

- Over 40 years experience treating cancer patients, of which over 30 years in oncology research, clinical care and clinical trials
- Pioneered clinical and single cell multiomics infrastructure



Michael Boyiadzis, MD, MHSc


Chief Medical Officer; Head of Research & Development

- Over 25 years translational and clinical research experience in hematology-oncology
- Professor of Medicine at the University of Pittsburgh, Senior Medical Director at Genentech/Roche
- Director of the Acute Leukemia Program and Clinical and Translational Research Center at UPMC Hillman Cancer Center

OUR TEAM HAS A CENTURY WORTH OF COMBINED EXPERIENCE IN ONCOLOGY AND BIOPHARMA



Leading AI-enabled precision medicine, OncoVerity brings transformative breakthrough therapies to patients



Exciting pipeline of innovative cancer therapies

Program	Indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
Cusatuzumab <i>In combination with Venetoclax + Azacitidine (Ven+Aza)</i>	1L AML					
Cusatuzumab <i>Monotherapy (with and without NK cells)</i>	R/R AML	Expected Phase 1b/2 in Q3 2026				
Cusatuzumab <i>In combination with Aza</i>	R/R MDS	Expected Phase 1b/2 in Q3 2026				
CD70 Targeting ADC	Undisclosed					
Novel Antibody (Under Negotiation)	Undisclosed					

**Cusatuzumab brings new hope to
AML patients based on promising
clinical evidence**

The OncoVerity logo is positioned in the bottom right corner of the graphic. It features the word "Onco" in a white, sans-serif font, followed by "Verity" in a bold, white, sans-serif font. The background of the graphic is a dark blue circle with a network of white dots and lines, and a teal-colored curved shape on the left side.

OncoVerity

Significant unmet need remains for AML patients

Standard of care (Ven+Aza) delivers modest outcomes for those unfit for intensive chemo and few options exist

An estimated **20K US cases of AML** are diagnosed annually with **11K deaths** (the second highest among blood cancers)

Median age of diagnosis is 69 and most patients are unfit for intensive chemo with just a **5-year survival rate of ~33%**

Up to 70% of patients achieving first CR will **relapse within 1 year**

New therapies must deliver deeper, broader, more durable responses to overcome limited survival and high relapse rates.



66%

1/3 of patients do not respond to SOC (CR+CRi of 66.4%) (*)



23%


MRD negativity, critical for overall survival (OS), achieved in only in 23.4% of responders (*)



52%

OS of only 14.7 months; 52% of patients eventually will relapse (*)


CD70 is an ideal target for application in cancer and autoimmune diseases



Cusatuzumab is a first-in-class anti-CD70 antibody with a dual mechanism of action

Two Mechanisms of Action


- 1 BLOCKS** CD70 proliferation and survival signal
- 2 KILLS** tumor cells through NK-ADCC



With CD70 expressed on the vast majority of blasts, cusatuzumab has a particularly strong biologic rationale in AML


CD70 is broadly implicated in various cancers

Expression on malignant cells




...with particularly strong biologic rationale in AML

Expression on 96-100% of AML blasts, selectively on LSCs, not HSCs



Safety and tolerability was established across ~400 AML patients




Safety


- Well tolerated with no MTD identified
- Safety profile consistent with Ven/Aza, with the exception of infusion-related reactions (IRRs)
- IRRs are typically low grade and manageable, and can be reduced with premedication

Cusatuzumab shows consistent additive efficacy across trials

**CULMINATE
Overall
Survival (*)**



**ELEVATE
Overall
Survival (*)**



	CULMINATE (Aza/Cusa 20mg/kg) N=52	ELEVATE (Ven/Aza/Cusa) N=44
ORR (Complete Remission + CRh + CRi)	40%	81%
CR	27%	50% 53% MRD
CRi	13%	31% negativity
Time to First Response	12 weeks	5.5 weeks
mOS	9.9 months	12.0 months
30-day Mortality	8%	4.5%
Transfusion Independence	52%	60%


**The OV-AML-1231 trial enables
an efficient and accelerated
route to market**



OncoVerity¹⁴

Cusatuzumab is currently in a randomized Phase 2 study in newly diagnosed AML patients unfit for intensive chemotherapy

Randomized, open label, multicenter, multinational study with 120 patients to enroll



OV-AML-1231 Endpoints

Primary Endpoint:

- OS

Secondary endpoint:

- CR/CRi/CRh/MLFS
- EFS
- MRD
- AE/SAEs

Exploratory Endpoints to Enable Precision Medicine

- High dimensional flow cytometry
- CITE-seq
- Duplex-Seq

Ready to execute on pipeline expansion; Cusatuzumab & AML are only the beginning



OncoVerity


Strong biologic and commercial rationale to expand Cusatuzumab into R/R MDS and R/R AML

Cusa Overcomes Major Hurdles Associated with Treatment of R/R AML and R/R MDS

- CD70 is aberrantly expressed on malignant hematopoietic stem and progenitor cells (HSPCs) in both AML and MDS
- Blocking CD70 leads to direct anti-leukemic effects, immune reactivation and eradication of disease initiating cells
- There is a critical need for new therapies in refractory AML/MDS as current treatments are associated with low responses, frequent relapse and are poorly tolerated
- Cusatuzumab may overcome these limitations through dual action on leukemia stem cells and immune restoration, making it a highly rational strategy for patients with refractory AML/MDS

J. Exp. Med. 2017, Nature Medicine 2020

Expansion to R/R AML and Higher-Risk MDS Doubles Est. Peak Sales to >\$4Bn



Scalable platform across oncology and autoimmune diseases, setting a new standard for drug development across the industry

Heme Malignancies (US Prevalence)

TCL (incl. CTCL)
(8K)

ALL
(7K)

ALL
(7K)

CLL
(19K)

CML
(19K)

DLBCL
(17K)

MCL
(17K)

MM
(17K)

Waldenstrom
Macroglobulinemia
(1.5K)

Solid Tumors (US Prevalence)

Lung
(236K)

Head and neck
cancer
(60K)

Ovarian cancer
(21K)

Pancreatic
cancer
(60K)

Renal cancer
(76K)

Auto-immune Diseases (US Prevalence)

Systemic lupus
erythematosus
(204K)

Rheumatoid
arthritis
(1.5M)

Sjogren
Syndrome
(17K)

Inflammatory
bowel disease
(2.5M)

Company highlights



OncoVerity is pioneering AI-enabled precision medicine, bringing transformative breakthrough therapies to patients



Cusatuzumab brings new hope to AML patients based on promising clinical evidence



The OV-AML-1231 trial enables an efficient and accelerated route to market



Ready to execute on pipeline expansion; Cusatuzumab and AML are only the beginning

Appendix



OncoVerity

Robust intellectual property portfolio

Composition of Matter Patents:

Several issued patents in the US, Europe, and other major markets directed to the lead anti-CD70 antibody with a term extending to 2032
Several patents pending for CD70 combination therapy with nucleoside metabolic inhibitors, with and without Venetoclax, in all major markets extending from 2038 to 2040

Method of Use Patents:

Several issued patents in the US, Europe, and other major markets directed to the treatment of myeloid malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), using the lead anti-CD70 antibody with a term extending to 2032

Pending applications in the US, Europe, and other major markets directed to treatment of myeloid malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), combination therapies that include the lead anti-CD70 antibody in combination with a second therapy, such as a BCL-2 inhibitor or a hypomethylating agent, or in combination with an antibody directed to a leukemic stem cell target (e.g., TIM-3), with terms extending from 2038 to 2041

Methods for Targeting Therapy to a Responsive Subject

Pending applications in the US and other major markets directed to methods for identifying a subject responsive to anti-CD-70 antibody treatment and methods for treating such a subject, with terms extending from 2040 to 2043

Will pursue patent term extensions of up to 5 years, where possible in various countries, based on delays in obtaining regulatory approval